Arcutis Biotherapeutics Inc (ARQT)vsRegeneron Pharmaceuticals Inc (REGN)
ARQT
Arcutis Biotherapeutics Inc
$23.89
+2.16%
HEALTHCARE · Cap: $3.00B
REGN
Regeneron Pharmaceuticals Inc
$793.74
+1.57%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 3248% more annual revenue ($15.53B vs $463.98M). REGN leads profitability with a 27.9% profit margin vs 6.2%. REGN trades at a lower P/E of 19.6x. REGN earns a higher WallStSmart Score of 66/100 (B-).
ARQT
Hold47
out of 100
Grade: D+
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+80.2%
Fair Value
$134.15
Current Price
$23.89
$110.27 discount
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$793.74
$610.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 59.3% year-over-year
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Trading at 13.6x book value
0.0% earnings growth
6.2% margin — thin
Weak financial health signals
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARQT
The strongest argument for ARQT centers on Revenue Growth. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : ARQT
The primary concerns for ARQT are Price/Book, EPS Growth, Profit Margin. A P/E of 108.6x leaves little room for execution misses.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ARQT profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
ARQT carries more volatility with a beta of 1.50 — expect wider price swings.
ARQT is growing revenue faster at 59.3% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (66/100 vs 47/100), backed by strong 27.9% margins and 16.7% revenue growth. ARQT offers better value entry with a 80.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arcutis Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?